托法替布在加拿大类风湿关节炎患者中的三年用药经验:患者特征与治疗模式
该研究基于加拿大托法替布支持项目,纳入2014年6月至2017年5月期间4276例类风湿关节炎患者,描述其基线特征、治疗模式和药物持续性。结果显示托法替布使用量增加,bDMARD初治患者比例上升;1年和2年持续性分别为62.7%和49.6%,中位药物生存约2年,既往bDMARD暴露与停药风险增加相关。
要点
- 托法替布在加拿大RA患者中使用增加,尤其是bDMARD初治和经1种bDMARD治疗后的患者。
- 总体1年和2年药物持续性分别为62.7%和49.6%,中位药物生存约2年。
- 既往bDMARD暴露者停药风险增加,年龄≥56岁和病程15-<20年与更高 retention 相关。
核心结论
- 托法替布在加拿大RA患者中使用增加,中位药物生存约2年,bDMARD初治患者和年龄≥56岁者持续性更高。
研究设计与样本
- 基于托法替布eXel支持项目的真实世界研究,纳入2014年6月1日至2017年5月31日加拿大RA患者4276例。
- 采用Kaplan-Meier法估计治疗持续性,Cox回归分析基线特征与停药的关系。
主要发现
- 4276例RA患者入组,托法替布使用增加,bDMARD初治患者处方比例亦增加。
- 3678例起始托法替布的患者中1226例(33.3%)停药,主要原因为疗效不足(35.7%)和不良事件(26.9%)。
- 治疗1年和2年持续性分别为62.7%和49.6%。
- 既往bDMARD暴露预测停药风险增加(vs bDMARD初治,P < 0.001)。
- 年龄56-65岁和>65岁(vs ≤45岁,P < 0.05)及病程15至<20年(vs <5年,P < 0.01)与更高 retention 相关。
关键数值与推荐
- bDMARD初治、经1种、经2种和经≥3种bDMARD患者的中位生存期分别为>730天、613天、667天和592天。
临床怎么用
- 在加拿大真实临床实践中,托法替布用于RA的持续性约2年,bDMARD初治患者和年龄≥56岁者可能更适合优先考虑。
局限性
- 数据来源于支持项目,可能存在选择偏倚;停药原因由患者报告,可能存在回忆偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe characteristics, treatment patterns and persistence in patients with RA treated with tofacitinib, an oral Janus kinase inhibitor, in Canadian clinical practice between 1 June 2014 and 31 May 2017. METHODS: Data were obtained from the tofacitinib eXel support programme. Baseline demographics and medication history were collected via patient report/special authorization forms; reasons for discontinuation were captured by patient report. Treatment persistence was estimated using Kaplan-Meier methods, with data censored at last follow-up. Cox regression was applied to analyse baseline characteristics associated with treatment discontinuation. RESULTS: The number of patients with RA enrolled from 2014 to 2017 was 4276; tofacitinib utilization increased during that period, as did the proportion of biologic (b) DMARD-naïve patients prescribed tofacitinib. Of patients who initiated tofacitinib, 1226/3678 (33.3%) discontinued, mostly from lack of efficacy (35.7%) and adverse events (26.9%). Persistence was 62.7% and 49.6% after 1 and 2 years of treatment, respectively. Prior bDMARD experience predicted increased tofacitinib discontinuation (vs bDMARD-naïve, P < 0.001). Increased retention was associated with older age (56-65 years and >65 years vs ⩽45 years; P < 0.05), and time since diagnosis of 15 to <20 years (vs <5 years; P < 0.01). In bDMARD-naïve, post-1 bDMARD, post-2 bDMARD and post-⩾3 bDMARD patients, median survival was >730, 613, 667 and 592 days, respectively. CONCLUSION: Since 2014, tofacitinib use in Canadian patients with RA increased, especially among bDMARD-naïve/post-1 bDMARD patients. Median drug survival was ∼2 years. Likelihood of persistence increased for bDMARD-naïve (vs bDMARD-experienced) patients and those aged ⩾56 (vs ⩽45) years.
引用
- Pope J, Bessette L, Jones N, et al. Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. Rheumatology (Oxford). 2020. PMID: 31410469. doi:10.1093/rheumatology/kez324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。